← All stocks

Trevi Therapeutics, Inc.

TRVI Scheduled selling only
CIK 0001563880 #1848 in the set updated 18 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$595.81K
$0.00 on a plan · $595.81K straight out of an exercise
Sold at will
$0.00
0 of 4 sales
Net
−$595.81K
$0.00 against sales at will

By person

6 insiders · 5 transactions
5.4×

Jennifer Good holds 5.4 times base salary in stock. $3.39M of shares against $622.38K in salary for 2025.

Salary from the company's own proxy. The shares are what Jennifer Good last reported holding, valued at $15.88, the price Common Stock was last bought or sold at on the open market here, on 15 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Heffernan Michael Thomas
Director
$595.81K (4) scheduled
−$595.81K
6,351
0.0045%
$100.85K
0.0%
SCIASCIA THOMAS
Chief Scientific Officer
221,373
0.1554%
$3.52M
0.0%
GOOD JENNIFER L
President & CEO
213,313
0.1497%
$3.39M
0.0%
Simon Farrell
Chief Commercial Officer
76,900
0.0540%
$1.22M
+68.5%
Delfini Lisa
Chief Financial Officer
64,660
0.0454%
$1.03M
+10.2%
Galletta Christopher
See Remarks
26,095
0.0183%
$414.39K
+279.8%
Insider
Date
Role
Action
Shares
Price
Amount
Heffernan Michael Thomas
15 Sep 2026
Director
Sold after exercise
100
$15.88
$1.59K
Heffernan Michael Thomas
15 Sep 2026
Director
Sold after exercise
20,952
$15.09
$316.17K
Heffernan Michael Thomas
15 Sep 2026
Director
Sold after exercise
100
$15.88
$1.59K
Heffernan Michael Thomas
15 Sep 2026
Director
Sold after exercise
18,321
$15.09
$276.46K
Galletta Christopher
2 Dec 2025
See Remarks
Exercised, kept
4,225
$0.51
$2.16K

What was left out

Form 4 filings counted 13
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 4
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 43,698
History held since 8 May 2019